Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy

Results from the SEARCH database

D. M. Moreira, M. R. Cooperberg, L. E. Howard, W. J. Aronson, C. J. Kane, Martha Kennedy Terris, C. L. Amling, M. Kuchibhatla, S. J. Freedland

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background:To evaluate the factors associated with positive bone scans after biochemical recurrence (BCR) following radical prostatectomy in both hormone-naive subjects and subjects after androgen-deprivation therapy (ADT).Methods:Retrospective analysis of 380 bone scans of 301 hormone-naive subjects and 214 bone scans of 137 subjects after ADT following BCR from the Shared Equal Access Regional Cancer Hospital database. Generalized estimating equations and local regression plots were used to evaluate bone scan positivity by patients' demographics, pathological features, PSA levels and kinetics.Results:Among hormone-naive subjects and subjects on ADT, bone scan positivity was seen in 24 (6%) and 65 (30%) subjects, respectively. In hormone-naive subjects, the higher prescan PSA, higher PSA velocity (PSAV) and shorter PSA doubling time (PSADT) were significantly associated with positive scans (P=0.008, P<0.001 and P<0.001, respectively). In subjects after ADT, the prescan PSA, PSAV and PSADT were significantly associated with positive scans (P=0.011, P<0.001 and P=0.002, respectively). Regression plots showed increased scan positivity with increasing PSA levels and shortening PSADT (all P<0.001) for both hormone-naive subjects and subjects after ADT. For a given PSA level and PSADT, subjects on ADT had higher bone scan positivity. Conclusions:In both hormone-naive subjects and subjects after ADT, more aggressive and advanced disease identified by higher PSA levels, higher PSAV and shorter PSADT were associated with higher bone scan positivity. For the same PSA level and PSADT, subjects after ADT had higher bone scan positivity than hormone-naive subjects. Therefore, PSA levels and kinetics may be used as selection criteria for bone scan in these patients.

Original languageEnglish (US)
Pages (from-to)91-96
Number of pages6
JournalProstate Cancer and Prostatic Diseases
Volume17
Issue number1
DOIs
StatePublished - Mar 1 2014

Fingerprint

Prostatectomy
Androgens
Databases
Hormones
Bone and Bones
Recurrence
Therapeutics
Cancer Care Facilities
Patient Selection
Demography

Keywords

  • PSA
  • disease-free survival
  • metastasis
  • mortality
  • prostatectomy

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy : Results from the SEARCH database. / Moreira, D. M.; Cooperberg, M. R.; Howard, L. E.; Aronson, W. J.; Kane, C. J.; Terris, Martha Kennedy; Amling, C. L.; Kuchibhatla, M.; Freedland, S. J.

In: Prostate Cancer and Prostatic Diseases, Vol. 17, No. 1, 01.03.2014, p. 91-96.

Research output: Contribution to journalArticle

@article{33622740b24a4bf28351597d1356c4c9,
title = "Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: Results from the SEARCH database",
abstract = "Background:To evaluate the factors associated with positive bone scans after biochemical recurrence (BCR) following radical prostatectomy in both hormone-naive subjects and subjects after androgen-deprivation therapy (ADT).Methods:Retrospective analysis of 380 bone scans of 301 hormone-naive subjects and 214 bone scans of 137 subjects after ADT following BCR from the Shared Equal Access Regional Cancer Hospital database. Generalized estimating equations and local regression plots were used to evaluate bone scan positivity by patients' demographics, pathological features, PSA levels and kinetics.Results:Among hormone-naive subjects and subjects on ADT, bone scan positivity was seen in 24 (6{\%}) and 65 (30{\%}) subjects, respectively. In hormone-naive subjects, the higher prescan PSA, higher PSA velocity (PSAV) and shorter PSA doubling time (PSADT) were significantly associated with positive scans (P=0.008, P<0.001 and P<0.001, respectively). In subjects after ADT, the prescan PSA, PSAV and PSADT were significantly associated with positive scans (P=0.011, P<0.001 and P=0.002, respectively). Regression plots showed increased scan positivity with increasing PSA levels and shortening PSADT (all P<0.001) for both hormone-naive subjects and subjects after ADT. For a given PSA level and PSADT, subjects on ADT had higher bone scan positivity. Conclusions:In both hormone-naive subjects and subjects after ADT, more aggressive and advanced disease identified by higher PSA levels, higher PSAV and shorter PSADT were associated with higher bone scan positivity. For the same PSA level and PSADT, subjects after ADT had higher bone scan positivity than hormone-naive subjects. Therefore, PSA levels and kinetics may be used as selection criteria for bone scan in these patients.",
keywords = "PSA, disease-free survival, metastasis, mortality, prostatectomy",
author = "Moreira, {D. M.} and Cooperberg, {M. R.} and Howard, {L. E.} and Aronson, {W. J.} and Kane, {C. J.} and Terris, {Martha Kennedy} and Amling, {C. L.} and M. Kuchibhatla and Freedland, {S. J.}",
year = "2014",
month = "3",
day = "1",
doi = "10.1038/pcan.2013.59",
language = "English (US)",
volume = "17",
pages = "91--96",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy

T2 - Results from the SEARCH database

AU - Moreira, D. M.

AU - Cooperberg, M. R.

AU - Howard, L. E.

AU - Aronson, W. J.

AU - Kane, C. J.

AU - Terris, Martha Kennedy

AU - Amling, C. L.

AU - Kuchibhatla, M.

AU - Freedland, S. J.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Background:To evaluate the factors associated with positive bone scans after biochemical recurrence (BCR) following radical prostatectomy in both hormone-naive subjects and subjects after androgen-deprivation therapy (ADT).Methods:Retrospective analysis of 380 bone scans of 301 hormone-naive subjects and 214 bone scans of 137 subjects after ADT following BCR from the Shared Equal Access Regional Cancer Hospital database. Generalized estimating equations and local regression plots were used to evaluate bone scan positivity by patients' demographics, pathological features, PSA levels and kinetics.Results:Among hormone-naive subjects and subjects on ADT, bone scan positivity was seen in 24 (6%) and 65 (30%) subjects, respectively. In hormone-naive subjects, the higher prescan PSA, higher PSA velocity (PSAV) and shorter PSA doubling time (PSADT) were significantly associated with positive scans (P=0.008, P<0.001 and P<0.001, respectively). In subjects after ADT, the prescan PSA, PSAV and PSADT were significantly associated with positive scans (P=0.011, P<0.001 and P=0.002, respectively). Regression plots showed increased scan positivity with increasing PSA levels and shortening PSADT (all P<0.001) for both hormone-naive subjects and subjects after ADT. For a given PSA level and PSADT, subjects on ADT had higher bone scan positivity. Conclusions:In both hormone-naive subjects and subjects after ADT, more aggressive and advanced disease identified by higher PSA levels, higher PSAV and shorter PSADT were associated with higher bone scan positivity. For the same PSA level and PSADT, subjects after ADT had higher bone scan positivity than hormone-naive subjects. Therefore, PSA levels and kinetics may be used as selection criteria for bone scan in these patients.

AB - Background:To evaluate the factors associated with positive bone scans after biochemical recurrence (BCR) following radical prostatectomy in both hormone-naive subjects and subjects after androgen-deprivation therapy (ADT).Methods:Retrospective analysis of 380 bone scans of 301 hormone-naive subjects and 214 bone scans of 137 subjects after ADT following BCR from the Shared Equal Access Regional Cancer Hospital database. Generalized estimating equations and local regression plots were used to evaluate bone scan positivity by patients' demographics, pathological features, PSA levels and kinetics.Results:Among hormone-naive subjects and subjects on ADT, bone scan positivity was seen in 24 (6%) and 65 (30%) subjects, respectively. In hormone-naive subjects, the higher prescan PSA, higher PSA velocity (PSAV) and shorter PSA doubling time (PSADT) were significantly associated with positive scans (P=0.008, P<0.001 and P<0.001, respectively). In subjects after ADT, the prescan PSA, PSAV and PSADT were significantly associated with positive scans (P=0.011, P<0.001 and P=0.002, respectively). Regression plots showed increased scan positivity with increasing PSA levels and shortening PSADT (all P<0.001) for both hormone-naive subjects and subjects after ADT. For a given PSA level and PSADT, subjects on ADT had higher bone scan positivity. Conclusions:In both hormone-naive subjects and subjects after ADT, more aggressive and advanced disease identified by higher PSA levels, higher PSAV and shorter PSADT were associated with higher bone scan positivity. For the same PSA level and PSADT, subjects after ADT had higher bone scan positivity than hormone-naive subjects. Therefore, PSA levels and kinetics may be used as selection criteria for bone scan in these patients.

KW - PSA

KW - disease-free survival

KW - metastasis

KW - mortality

KW - prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=84894083618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894083618&partnerID=8YFLogxK

U2 - 10.1038/pcan.2013.59

DO - 10.1038/pcan.2013.59

M3 - Article

VL - 17

SP - 91

EP - 96

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 1

ER -